Compare Dyne Therapeutics Inc. Common Stock (DYN) vs Nu Holdings Ltd (NU) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Dyne Therapeutics Inc. Common Stock vs Nu Holdings Ltd — how do they compare? Dyne Therapeutics Inc. Common Stock trades at $15.09 (market cap $2.86B), while Nu Holdings Ltd trades at $14.7 (market cap $75.26B). The key difference: Nu Holdings Ltd is far larger — about 26.3× Dyne Therapeutics Inc. Common Stock's market cap, and Nu Holdings Ltd is trading nearer its 52-week high, Dyne Therapeutics Inc. Common Stock nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Dyne Therapeutics Inc. Common Stock for 0 Days and Nu Holdings Ltd for 53 Days on average.
| DYN | NU | |
|---|---|---|
Market Cap | $2.86B | $75.26B |
Volume | 3,341,579 | 60,119,584 |
Sector | Health | Financials |
52-Week High | $26.78 | $18.76 |
52-Week Low | $14.60 | $11.60 |
Typical Hold Time | 0 Days | 53 Days |
Enterprise Value | $2.18B | $97.88B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Dyne Therapeutics (DYN) trades at $15.30, down 4.14% on the day, reflecting recent volatility amid mixed clinical trial news. The stock is in a neutral technical position with immediate support at $15 and resistance at $16. Fundamentally, the company is a clinical-stage biotech with no revenue, reporting a net loss of $446.21M in 2025, but maintains strong analyst support with an 85.7% buy rating and a $35.20 consensus price target. Recent news highlights progress in Phase 1/2 trials for neuromuscular diseases and a $375M public offering in July 2026 to fund development.
The investment case hinges on clinical success, offering significant upside to the price target, but carries high risk due to pre-revenue status, dependence on trial outcomes, and negative cash flow from operations. Investor sentiment is cautiously optimistic, buoyed by analyst confidence, though volatility from sector-specific news remains a near-term challenge.
NU stock trades at $14.93, down 6.75% over 24 hours amid recent volatility. The technical outlook is bullish based on moving averages, though the 6-day RSI at 88.3 suggests overbought conditions. Fundamentally, the company shows strong growth with revenue rising from $3.0B in 2022 to $10.63B in 2025 and net income margin improving to 26.99%. Recent news includes denial of Monzo acquisition talks, causing price swings.
The outlook remains positive given robust fundamentals and analyst consensus, but risks include high valuation multiples, credit concentration, and acquisition speculation volatility. Upside to the $16.53 price target offers potential, though investor caution is warranted near technical resistance.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Dyne Therapeutics Inc. Common Stock
Dyne Therapeutics, Inc. is a clinical-stage biotechnology company developing therapeutics for genetically driven neuromuscular diseases, including Duchenne muscular dystrophy and myotonic dystrophy type 1, with additional preclinical programs for facioscapulohumeral muscular dystrophy and Pompe disease.
Read more on DYN →About Nu Holdings Ltd
Nu Holdings Ltd is engaged in providing digital banking services. It offers several financial services such as Credit cards, Personal Account, Investments, Personal Loans, Insurance, Mobile payments, Business Account, and Rewards.
Read more on NU →
